Q3 2024 DENTSPLY SIRONA Inc Earnings Call Transcript
Key Points
- Dentsply Sirona Inc (XRAY) reported $951 million in revenue for Q3 2024, with organic sales up 1.3%, driven by timing of EDS sales.
- The launch of Primescan 2 in September contributed to growth in the CAD/CAM segment, marking a milestone in digital dentistry.
- The company successfully launched Exmark Pro Plus in the US, exceeding full-year projections by the end of Q3.
- Dentsply Sirona Inc (XRAY) has executed over 70% of its phase two transformation activities, aiming for full run-rate savings by the end of 2025.
- The company has made significant progress in its ERP rollout, with successful deployments in the UK and the US, enhancing operational efficiency.
- Dentsply Sirona Inc (XRAY) announced a voluntary suspension of sales, marketing, and shipments of byte aligners and impression kits due to regulatory reviews, impacting revenue.
- The company recorded a $500 million non-cash after-tax charge related to goodwill in the orthodontic and implant solution segment due to macroeconomic pressures.
- Organic sales in the orthodontic and implant solution segment declined by 3.9%, with a notable decline in the US and Europe.
- The company revised its full-year 2024 outlook, expecting organic sales to be down 2.5% to 3.5%, citing market pressures and challenges with byte.
- Dentsply Sirona Inc (XRAY) is facing ongoing macroeconomic challenges, including high interest rates and reduced patient traffic in key markets like Japan and China.
Good day and thank you for standing by. Welcome to the Q3 2024 Dentsply Sarona earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today. Andrea Daley, Vice President of Investor Relations.
Thank you, operator and good morning, everyone. Welcome to the Dense by Corona third quarter, 2024 earnings call. Joining me for today's call is Simon Campion, Chief Executive Officer Glenn Coleman, Chief Financial Officer and Richard Rosenzweig EVP Corporate Development and General Counsel.
I'd like to remind you that an earnings press release and slide presentation related to the call are available in the investors section of our website at www.dentsplysirona.com.
Before we begin, please take a moment to read the forward-looking statements in our earnings press release. During today's call. We may
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
